Chris Hoggett

England

Carpmaels & Ransford LLP · Chris is a partner in the Pharmaceuticals team at Carpmaels & Ransford. He handles cases relating to new chemical entities, combinations, formulations, polymorphs, dosage regimens and clinical trial inventions for innovator clients such as Gilead and Novartis. Chris is experienced as lead counsel in multiparty EPO opposition and appeal proceedings and has successfully represented clients on a number of commercially important patents protecting blockbuster products. His work often involves supporting parallel litigation, both in an advisory capacity and in tailoring EPO strategies to align with his clients’ commercial objectives in the courts. In addition to his largely contentious work with big pharma, he supports clinical stage pharmaceutical companies such as KalVista Pharmaceuticals. He is also a registered UPC representative. Chris is recommended by IAM Patent 1000 and is cited as a “trusted practitioner, [who] easily understands the relevant details and offers creative solutions to tricky problems. He is a strong oral advocate and is self-assured while always remaining open to new ideas” (IAM Patent 1000, 2023). He is recognised as a “key lawyer” in Legal 500 and as a Band 1 practitioner in Chambers. Sources highlight that he “has huge experience and technical knowledge” and that he is “very knowledgeable and thorough in his legal advice. He is a pleasure to work with” (Chambers & Partners, 2025).

England